Wakefield, D; McCluskey, P; Wildner, G; Thurau, S; Carr, G; Chee, SP; Forrester, J; ... Pre-treatment Assessment Review Panel, .; + view all Wakefield, D; McCluskey, P; Wildner, G; Thurau, S; Carr, G; Chee, SP; Forrester, J; Dick, A; Hudson, B; Lightman, S; Smith, J; Tugal-Tutkun, I; Pre-treatment Assessment Review Panel, .; - view fewer (2017) Inflammatory eye disease: pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. Autoimmunity Reviews , 16 (3) pp. 213-222. 10.1016/j.autrev.2017.01.003.

Preview

Text Wakefield_Inflammatory_eye_disease_AAM(website).pdf - Accepted Version Download (204kB) | Preview

Abstract

AIM: To outline recommendations from an expert committee on the assessment and investigation of patients with severe inflammatory eye disease commencing immunosuppressive and/or biologic therapy. METHOD: The approach to assessment is based on the clinical experience of an expert committee and a review of the literature with regard to corticosteroids, immunosuppressive drug and biologic therapy and other adjunct therapy in the management of patients with severe sight-threatening inflammatory eye disease. CONCLUSION: We recommend a careful assessment and consultative approach by ophthalmologists or physicians experienced in the use of immunosuppressive agents for all patients commencing immunosuppressive and/or biologic therapy for sight threatening inflammatory eye disease with the aim of preventing infection, cardiovascular, metabolic and bone disease and reducing iatrogenic side effects.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item